NCT00044733View on ClinicalTrials.gov

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2000

Study Completion Date

September 30, 2004

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Mylotarg (gemtuzumab ozogamicin) Injection

Trial Locations (13)

14215

Buffalo

14642

Rochester

25304

Charleston

32209

Jacksonville

44708

Canton

53792

Madison

66061

Olathe

72211

Little Rock

77030

Houston

96813

Honolulu

06102

Hartford

08103

Camden

08629

Trenton

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00044733 - Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant | Biotech Hunter | Biotech Hunter